Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
|Videos|November 16, 2022
Dr. Goldfischer highlights the value of PSMA-PET imaging in urology
Author(s)Urology Times staff
“PSMA scanning is definitely a game-changer with regard to imaging in advanced prostate cancer in urology,” says Evan R. Goldfischer, MD.
Advertisement
In this interview, Evan R. Goldfischer, MD, MBA, FACS, discusses the value of PSMA-PET imaging in prostate cancer. Goldfischer chaired a discussion on the rapidly emeging modalitiy during the
Advertisement
Related to this article
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Variation in PSMA PET Adoption for Prostate Cancer Care
3
FDA grants 510(k) clearance to OpenFlo urinary catheter
4
FDA grants fast track designation to VIR-5500 for mCRPC
5